<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2901256776
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SIMVA 10 MG COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SIMVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Simva<sup>TM</sup> is a medicine used to lower levels of total cholesterol, &ldquo;bad&rdquo; cholesterol<br />(LDL cholesterol), and fatty substances called triglycerides in the blood. In addition,<br />Simva<sup>TM</sup> raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).<br />You should stay on a cholesterol-lowering diet while taking this medicine.<br />Simva<sup>TM</sup> is a member of the class of drugs called statins.<br />Simva<sup>TM</sup> is used along with diet if you have:<br />&bull; a raised cholesterol level in your blood (primary hypercholesterolaemia) or elevated<br />fat levels in your blood (mixed hyperlipidaemia).<br />&bull; a hereditary illness (homozygous familial hypercholesterolaemia) that increases the<br />cholesterol level in your blood. You may also receive other treatments.<br />&bull; coronary heart disease (CHD) or are at high risk of CHD (because you have<br />diabetes, history of stroke, or other blood vessel disease). Simva<sup>TM</sup> may prolong your<br />life by reducing the risk of heart disease problems, regardless of the amount of<br />cholesterol in your blood.<br />In most people, there are no immediate symptoms of high cholesterol. Your doctor<br />can measure your cholesterol with a simple blood test. Visit your doctor regularly,<br />keep track of your cholesterol, and discuss your goals with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Simva<sup>TM</sup></strong><br />&bull; if you are allergic (hypersensitive) to simvastatin or any of the other ingredients of<br />Simva<sup>TM</sup> Tablets (see Section 6: Further Information).<br />&bull; if you currently have liver problems.<br />&bull; if you are pregnant or breast-feeding.<br />&bull; if you are taking one or more of the following drugs at the same time:<br />- itraconazole, ketoconazole, or posaconazole (medicines for fungal infections).<br />- erythromycin, clarithromycin, or telithromycin (antibiotics for infections).<br />- HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir (HIV<br />protease inhibitors are used for HIV infections).<br />- nefazodone (a medicine for depression).<br />- gemfibrozil (a medicine for lowering cholesterol).<br />- ciclosporin (a medicine often used in organ transplant patients).<br />- danazol (a man-made hormone used to treat endometriosis).<br />Ask your doctor if you are not sure if your medicine is listed above.<br /><strong>Take special care with Simva<sup>TM</sup></strong><br />&bull; Tell your doctor about all your medical conditions including allergies.<br />&bull; Tell your doctor if you drink large amounts of alcohol.<br />&bull; Tell your doctor if you have ever had liver disease. SimvaTM may not be right for<br />you.<br />&bull; Tell your doctor if you are due to have an operation. You may need to stop taking<br />SimvaTM tablets for a short time.<br />&bull; Your doctor should do a blood test before you start taking SimvaTM. This is to check<br />how well your liver is working.<br />&bull; Your doctor may also want you to have blood tests to check how well your liver is<br />working after you start taking SimvaTM.<br />&bull; While you are on this medicine your doctor will monitor you closely if you have<br />diabetes or are at risk of developing diabetes. You are likely to be at risk of<br />developing diabetes if you have high levels of sugars and fats in your blood, are<br />overweight and have high blood pressure.<br />&bull; Tell your doctor if you have severe lung disease.<br />Liver function tests should be performed prior to and at 12 week following both the<br />initiation of therapy and any elevation of dose, and periodically (e .g., semiannually)<br />thereafter. Liver enzyme changes generally occur in the first 3 months of treatment<br />with SimvaTM.<br />Increases in HbAlc and fasting serum glucose levels have been reported with<br />HMG-CoA reductase inhibitors, including SimvaTM.<br /><strong>Contact your doctor immediately if you experience unexplained muscle pain,<br />tenderness, or weakness. This is because on rare occasions, muscle problems can<br />be serious, including muscle breakdown resulting in kidney damage; and very<br />rare deaths have occurred.</strong><br />The risk of muscle breakdown is greater at higher doses of SimvaTM, particularly the<br />80mg dose. The risk of muscle breakdown is also greater in certain patients.<br />Talk with your doctor if any of the following applies:<br />&bull; you consume large amounts of alcohol<br />&bull; you have kidney problems.<br />&bull; you have thyroid problems.<br />&bull; you are 65 years or older.<br />&bull; you are female.<br />&bull; you have ever had muscle problems during treatment with cholesterol-lowering<br />medicines called &ldquo;statins&rdquo; or fibrates.<br />&bull; you or a close family member have a hereditary muscle disorder.<br /><strong>Using other medicines</strong><br />It is particularly important to tell your doctor if you are taking any of the following<br />drugs. Taking SimvaTM with any of these drugs can increase the risk of muscle<br />problems (some of these have already been listed in the above section &ldquo;Do not take<br />Simva<sup>TM</sup>&rdquo;).<br />&bull; ciclosporin (a medicine often used in organ transplant patients).<br />&bull; danazol (a man-made hormone used to treat endometriosis).<br />&bull; medicines like itraconazole, ketoconazole, fluconazole or posaconazole (medicines<br />for fungal infections).<br />&bull; fibrates like gemfibrozil and bezafibrate (medicines for lowering cholesterol).<br />&bull; erythromycin, clarithromycin, telithromycin, or fusidic acid (medicines for bacterial<br />infections).<br />&bull; HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir<br />(medicines for AIDS).<br />&bull; nefazodone (a medicine for depression).<br />&bull; amiodarone (a medicine for an irregular heartbeat).<br />&bull; verapamil, diltiazem or amlodipine (medicines for high blood pressure, chest pain<br />associated with heart disease, or other heart conditions).<br />&bull; colchicine (a medicine used to treat gout).<br />As well as the medicines listed above, tell your doctor or pharmacist if you are taking<br />or have recently taken any other medicines, including those obtained without a<br />prescription. In particular, tell your doctor if you are taking any of the following:<br />&bull; medicines to prevent blood clots, such as warfarin, phenprocoumon or<br />acenocoumarol (anticoagulants).<br />&bull; fenofibrate (another medicine for lowering cholesterol).<br />&bull; niacin (another medicine for lowering cholesterol).<br />&bull; rifampicin (a medicine used to treat tuberculosis).<br />Also tell your doctor if you are taking niacin (nicotinic acid) or a niacin-containing<br />product and are Chinese.<br />You should also tell any doctor who is prescribing a new medicine for you that you<br />are taking Simva<sup>TM</sup>.<br /><strong>Taking Simva<sup>TM</sup> with food and drink</strong><br />Grapefruit juice contains one or more components that alter how the body uses some<br />medicinal products, including Simva<sup>TM</sup>. Consuming grapefruit juice should be<br />avoided.<br /><strong>Pregnancy and Breast-feeding</strong><br />Do not take SimvaTM if you are pregnant, trying to get pregnant or think you may be<br />pregnant. If you get pregnant while taking SimvaTM, stop taking it immediately and<br />contact your doctor. Do not take SimvaTM if you are breast-feeding, because it is not<br />known if the medicine is passed into breast milk.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Children</strong><br />Safety and effectiveness have been studied in 10-17 year old boys and in girls who<br />had started their menstrual period at least one year before (see Section 3: How to<br />take SimvaTM). SimvaTM has not been studied in children under the age of 10 years.<br />For more information, talk to your doctor.<br /><strong>Driving and using machines</strong><br />SimvaTM is not expected to interfere with your ability to drive or to use machinery.<br />However, it should be taken into account that some people get dizzy after taking<br />SimvaTM.<br /><strong>Important information about some of the ingredients of Simva<sup>TM</sup></strong><br />One of the ingredient Ludipress of SimvaTM tablets contains lactose. If you have an<br />intolerance to some sugars, please speak to your pharmacist or doctor before taking<br />this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Simva<sup>TM</sup> exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.</p><p>You should stay on a cholesterol-lowering diet while taking Simva<sup>TM</sup>.<br />The dose is SimvaTM 10 mg, 20 mg, 40 mg, or 80 mg by mouth once a day.<br />For children (10-17 years old), the recommended usual starting dose is 10 mg a day<br />in the evening. The maximum recommended dose is 40 mg a day.<br />The 80 mg dose is only recommended for adult patients with very high cholesterol<br />levels and at high risk of heart disease problems who have not reached their<br />cholesterol goal on lower doses.<br />Your doctor will determine the appropriate dose for you, depending on your<br />condition, your current treatment and your personal risk status.<br />Take Simva<sup>TM</sup> in the evening. You can take it with or without food. The usual<br />starting dose is 10, 20 or, in some cases, 40 mg a day. Your doctor may adjust your<br />dose after at least 4 weeks to a maximum of 80 mg a day. Do not take more than 80<br />mg a day. Your doctor may prescribe lower doses, particularly if you are taking<br />certain medicinal products listed above or have certain kidney conditions. Keep<br />taking Simva<sup>TM</sup> unless your doctor tells you to stop.<br />If your doctor has prescribed Simva<sup>TM</sup> along with any bile acid sequestrant<br />(medicines for lowering cholesterol), you should take SimvaTM at least 2 hours before<br />or 4 hours after taking the bile acid sequestrant.<br /><strong>If you take more Simva<sup>TM</sup> than you should</strong><br />&bull; please contact your doctor or nearest hospital for advice.<br /><strong>If you forget to take Simva<sup>TM</sup></strong><br />&bull; do not take an extra dose, just take your normal amount of SimvaTM at the usual<br />time the next day.<br /><strong>If you stop taking Simva<sup>TM</sup></strong><br />&bull; your cholesterol may rise again.<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Simva<sup>TM</sup> can cause side effects, although not everybody gets<br />them.<br />The following terms are used to describe how often side effects have been reported:<br />&bull; Rare (occurring in 1 or more of 10,000 and less than 1 of 1000 patients treated).<br />&bull; Very rare (occurring in less than 1 of 10,000 patients treated).<br />&bull; Frequency not known.<br />The following rare serious side effects were reported.<br /><strong>If any of these serious side effects happen, stop taking the medicine and tell your<br />doctor immediately or go to the emergency room at your nearest hospital.</strong><br />&bull; muscle pain, tenderness, weakness, or cramps. On rare occasions, these muscle<br />problems can be serious, including muscle breakdown resulting in kidney damage;<br />and very rare deaths have occurred.<br />&bull; hypersensitivity (allergic) reactions including:<br />&bull; swelling of the face, tongue and throat which may cause difficulty in breathing.<br />&bull; severe muscle pain usually in the shoulders and hips.<br />&bull; rash with weakness of limbs and neck muscles.<br />&bull; pain or inflammation of the joints. &bull; inflammation of the blood vessels.<br />&bull; unusual bruising, skin eruptions and swelling, hives, skin sensitivity to the sun,<br />fever, flushing. &bull; shortness of breath and feeling unwell.<br />&bull; lupus-like disease picture (including rash, joint disorders, and effects on<br />blood cells). &bull; inflammation of the liver with yellowing of the skin and<br />eyes, itching, dark-coloured urine or pale-coloured stool, liver failure (very rare).<br />&bull; inflammation of the pancreas often with severe abdominal pain.<br />The following side effects have also been reported rarely:<br />&bull; low red blood cell count (anaemia). &bull; numbness or weakness of the arms and legs.<br />&bull; headache, tingling sensation, dizziness. &bull; digestive disturbances (abdominal pain,<br />constipation, flatulence, indigestion, diarrhoea, nausea, vomiting).<br />&bull; rash, itching, hair loss. &bull; weakness.<br />&bull; trouble sleeping (very rare). &bull; poor memory (very rare).<br />The following side effects have also been reported but the frequency cannot be<br />estimated from the available information (frequency not known):<br />&bull; erectile dysfunction. &bull; depression.<br />&bull; inflammation of the lungs causing breathing problems including persistent cough<br />and/or shortness of breath or fever.<br />&bull; tendon problems, sometimes complicated by rupture of the tendon.<br />Additional possible side effects reported with some statins:<br />&bull; sleep disturbances, including nightmares. &bull; memory loss. &bull; sexual difficulties.<br />&bull; diabetes. This is more likely if you have high levels of sugars and fats in your<br />blood, are overweight and have high blood pressure. Your doctor will monitor you<br />while you are taking this medicine.<br /><strong>Laboratory Values</strong><br />Elevations in some laboratory blood tests of liver function and a muscle enzyme<br />(creatine kinase) have been observed.<br />There have been rare post marketing reports of cognitive impairment (e.g., memory<br />loss, forgetfullness, amnesia, memory impairment and confusion) associated with<br />statin use. These cognitive issues have been reported for all statins. The reports are<br />generally non-serious, and reversible upon, statin discontinuation, with variable<br />times to symptom onset (1 day to years) and symptom resolution (median of 3<br />weeks).<br />If any of the side effects gets serious, or if you notice any side effects not listed in<br />this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30 &ordm;C.<br />Do not use SimvaTM after the expiry date (&quot;EXP&quot;) which is stated on the carton.<br />Keep blister in outer carton in order to protect from moisture.<br />Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will<br />help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Simva<sup>TM</sup> contains<br />The active substance is simvastatin (10 mg, 20 mg, or 40 mg).<br />The other ingredients are butylated hydroxyl anisole, citric acid monohydrate,<br />croscarmellose sodium, crospovidone, hydroxypropyl cellulose, ludipress,<br />magnesium stearate, microcrystalline cellulose, opadry white, polysorbate 80,<br />povidone, pregelatinised starch, propylene glycol, silicon dioxide colloidal,<br />simethicone, talc and purified water.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What SimvaTM looks like and contents of the pack
SimvaTM 10 mg Tablets: White to off white, oval biconvex film coated tablets,
engraved with 'JP33' on one side and plain on the other side.
SimvaTM 20 mg Tablets: White to off white, oval biconvex, film coated tablets,
engraved with 'JP 34' on one side and plain on the other side.
SimvaTM 40 mg Tablets: White to off white, round biconvex, film coated tablets,
engraved with 'JP 35' on one side and plain on the other side.
SimvaTM 10 mg Tablets are available in a box of 30 Film Coated Tablets.
SimvaTM 20 mg Tablets are available in a box of 30 Film Coated Tablets.
SimvaTM 40 mg Tablets are available in a box of 30 Film Coated Tablets.
Not all packs may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02-2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سيمڤا&nbsp;هو دواء يستخدم لخفض مستويات الكوليستيرول الكلى ، الكوليستيرول &quot;الضار&quot; (الكوليستيرول المنخفض الكثافة) و المواد الدهنية المسماة بالدهون الثلاثية فى الدم.</p><p>بالإضافة إلى ذلك يقوم سيمڤا برفع&nbsp;مستويات الكوليستيرول &quot;الجيد&quot; (الكوليستيرول المرتفع الكثافة) .</p><p>يجب عليك إتباع نظام غذائى منخفض الكوليستيرول طوال فترة العلاج.</p><p>سيمڤا&nbsp;ينتمى إلى مجموعة من الأدوية تسمى &quot;الستاتينات&quot; و هى أدوية منظمة للدهون.</p><p>يستخدم سيمڤا&nbsp;إلى جانب النظام الغذائى إذا كنت تعانى من الآتى:</p><p>&bull; ارتفاع مستوى الكوليستيرول فى الدم (فرط كوليستيرول الدم الأوّلى) أو ارتفاع مستويات الدهون فى الدم<br />(فرط دهون الدم المختلط).<br />&bull; مرض وراثى مثل فرط كوليستيرول الدم متماثل الزيجوت الذى يرفع من مستوى الكوليستيرول فى دمك . قد<br />تتلقى أيضا بعض الأدوية الأخرى لعلاج هذا المرض.<br />&bull; أمراض الشريان التاجى أو معرّض لخطر الإصابة بأمراض الشريان التاجى (لأنك مصاب بداء السكرى،<br />لديك تاريخ للإصابة بالسكتة الدماغية أو غيرها من أمراض الأوعية الدموية).<br />فى إطالة حياتك عن طريق تقليل خطر الإصابة بأمراض القلب بغض النظر عن كمية &trade; قد يساهم سيمڤا<br />الكوليستيرول فى دمك.<br />عند معظم الأشخاص لا توجد أعراض فورية لإرتفاع الكوليستيرول فى الدم. يمكن لطبيبك أن يقيس مستوى<br />الكوليستيرول فى دمك عن طريق إجراء اختبار فحص دم بسيط. قم بزيارة طبيبك بانتظام ، و احتفظ بسجل<br />مستوى الكوليستيرول الخاص بك و ناقش أهدافك مع طبيبك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول سيمڤا&trade; فى الحالات الآتية:</p><p>&bull; إذا كانت لديك حساسية مفرطة لسيمڤا&nbsp;أو أى من المكونات الأخرى لهذا الدواء ( انظر الجزء رقم ٦)</p><p>&bull; إذا كنت تعانى حاليا من مشاكل الكبد.<br />&bull; إذا كنتِ حاملا أو مرضع.<br />&bull; إذا كنت تتناول واحدا أو أكثر من هذه الأدوية فى نفس الوقت مع سيمڤا&trade;:<br />- كيتوكونازول، إيتراكونازول، بوساكونازول (أدوية مضادة للفطريات).<br />- إريثروميسين، كلاريثروميسين، تليثروميسين (مضادات حيوية لعلاج العدوى).<br />- الأدوية المستخدمة لعلاج ڤيرس نقص المناعة البشرية مثل ريتوناڤير، ساكويناڤير، إنديناڤير، نيلفيناڤير<br />(مثبطات الإنزيم البروتينى المستخدمة لعلاج ڤيرس نقص المناعة البشرية).<br />- نيفازودون (دواء لعلاج الإكتئاب).<br />- چيمفيبروزول (دواء لخفض الكوليستيرول).<br />- سيكلوسبورين (دواءغالبا ما يستخدم لمرضى زراعة الأعضاء).<br />- دانازول (هرمون مصنّع يستخدم لعلاج الانتباذ البطانى الرحمى).</p><p>اسأل طبيبك إذا كنت غير متأكد من انك تتناول أى من الأدوية السابق ذكرها.</p><p><br /><strong>أعط عناية خاصة عند تناول سيمڤا&trade; فى الحالات الآتية: </strong><br />&bull; اخبر طبيبك بكل الحالات المرضية التى تعانى منها بما فى ذلك الحساسية.<br />&bull; اخبر طبيبك إذا كنت تشرب كميات كبيرة من الكحول.<br />&bull; اخبر طبيبك إذا كنت قد عانيت من أمراض الكبد فى أى وقت مضى. سيمڤا&trade;قد يكون غير مناسب لك حينها.<br />&bull; اخبر طبيبك إذا كنت على وشك القيام بعملية جراحية ، قد تحتاج أن توقف استخدام أقراص سيمڤا&trade; لفترة<br />قصيرة.<br />&bull;يجب أن يجرى لك طبيبك بعض فحوصات الدم قبل البدء فى أخذ سيمڤا&trade; ليتحقق من مدى جودة وظائف الكبد.</p><p>&bull; قد يحتاج طبيبك أن يجرى لك بعض فحوصات الدم أثناء العلاج أيضا ليتحقق من مدى جودة وظائف الكبد بعد&nbsp;البدء فى أخذ سيمڤا.&nbsp;</p><p>&bull; أثناء تلقيك هذا الدواء سوف يقوم طبيبك بمتابعتك عن قرب إذا كنت مريض بداء السكرى أو معرض للإصابة<br />بمرض السكرى. أنت معرض لخطر الإصابة بداء السكرى إذا كانت مستويات السكر و الدهون مرتفعة فى دمك<br />، تعانى من زيادة فى وزنك و مصاب بارتفاع ضغظ الدم.<br />&bull; اخبر طبيبك إذا كنت تعانى من مرض رئوى شديد.<br />يجب أن يتم عمل اختبارات وظائف الكبد قبل وبعد ۱۲ أسبوع بعد كل من بدء العلاج وأي ارتفاع للجرعة، و<br />بعد ذلك بشكل دوري (مثل: نصف سنوي) . تغييرات انزيمات الكبد يحدث عادة خلال الثلاث أشهر الأولى من<br />العلاج مع سيمفا .&trade;<br />وقد تم الإبلاغ عن زيادة في مستويات الهيموجلوبين السكري(HbAlc) و الجلوكوز في مصل الدم صائماً مع<br />مثبطات لإنزيم . (HMG-COA Reductase) بما في ذلك سيمفا .&trade;<br /><strong>اتصل بطبيبك على الفور إذا عانيت من آلام، ليونة أو ضعف فى العضلات غير معروف السبب . و ذلك لأنه<br />فى حالات نادرة مشاكل العضلات قد تصبح خطيرة و تؤدى إلى تكسُر العضلات مما يسبب فشل كلوى و فى<br />بعض الحالات النادرة جدا يؤدى الى الوفاة.</strong><br />خطر الإصابة بتكسُر العضلات يزداد عند تناول الجراعات الكبيرة من سيمڤا&trade; خاصة جرعة ۸۰ ملجم . كما<br />يكون خطر الإصابة بتكسُر العضلات أكبر عند بعض المرضى.<br />تحدث إلى طبيبك إذا انطبقت عليك إحدى الحالات الآتية:<br />&bull; تستهلك كميات كبيرة من الكحول.<br />&bull; لديك مشاكل فى الكلى.<br />&bull; لديك مشاكل فى الغدة الدرقية.<br />&bull; تبلغ من العمر ٦٥ عاما أو أكثر.<br />&bull; أنت أنثى.<br />&bull; إذا عانيت من قبل من مشاكل فى العضلات أثناء علاجك بالأدوية المخفضة للكوليستيرول &quot;الستاتينات&quot; أو<br />&quot;الفيبرات&quot;.<br />&bull; أنت أو أحد أفراد الأسرة المقربين تعانى من اضطراب وراثى فى العضلات.<br /><strong>تناول أدوية أخرى</strong><br />من المهم بصفة خاصة أن تخبر طبيبك إذا كنت تتناول أى من الأدوية التالية:<br />تناول سيمڤا مع أى من هذه الأدوية من الممكن أن يزيد من خطر الإصابة بمشاكل العضلات (بعض من هذه &trade;<br />المشاكل قد تم ذكرها بالفعل فى الجزء العلوى تحت عنوان &quot; لا تتناول سيمڤا&trade; فى الحالات الآتية&quot;).<br />&bull; سيكلوسبورين (دواء يستخدم غالبا لمرضى زراعة الأعضاء).<br />&bull; دانازول (هرمون مصنّع يستخدم لعلاج الانتباذ البطانى الرحمى).<br />&bull; كيتوكونازول، إيتراكونازول، بوساكونازول (أدوية مضادة للفطريات).<br />&bull; الفيبرات مثل چيمفيبروزول و بنزافيبرات (أدوية لخفض الكوليستيرول).<br />&bull; إريثروميسين، كلاريثروميسين، تليثروميسين أو حمض الفيوسيديك (مضادات حيوية لعلاج العدوى<br />البكتيرية).<br />&bull; الأدوية المستخدمة لعلاج ڤيرس نقص المناعة البشرية مثل ريتوناڤير، ساكويناڤير، إنديناڤير، نيلفيناڤير<br />(مثبطات الإنزيم البروتينى المستخدمة لعلاج ڤيرس نقص المناعة البشرية).<br />&bull; نيفازودون (دواء لعلاج الإكتئاب).<br />&bull; أميودارون (دواء يستخدم لعلاج عدم انتظام ضربات القلب).<br />&bull; ڤيراباميل، دلتيازيم أو أملوديبين (أدوية تستخدم لعلاج ضغط الدم المرتفع، ألم الصدر الناتج عن أمراض القلب<br />أو حالات القلب المرضية الأخرى).<br />&bull; الكولشيسين (دواء يستخدم لعلاج مرض النقرص).<br />بجانب الأدوية الأخرى ، يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو أخذت مؤخرا أية أدوية أخرى بما<br />فيها الأدوية التى تُصرف بدون وصفة طبية. خاصة إذا كنت تتناول أى من الأدوية التالية:<br />&bull; الأدوية المانعة لتجلط الدم مثل الوارفارين، فينوبروكومون أو أسينوكومارول (مضادات التخثر).<br />&bull; فينوفيبرات (دواء آخر لخفض مستوى الكوليسترول).<br />&bull; نياسين (دواء آخر لخفض مستوى الكوليسترول).<br />&bull; ريفامبيسين (دواء يستخدم لعلاج الدرن).<br />اخبر طبيبك إذا كنت تتناول نياسين(حمض النيكوتينك) أو أى منتج يحتوى على النياسين و أنت صينى .<br />.&trade; يجب عليك أيضا أن تخبر طبيبك الذى يصف لك دواء جديد أنك تتناول سيمڤا</p><p><strong>&nbsp; تناول سيمڤا مع الطعام و الشراب</strong></p><p>عصير الجريب فروت يحتوى على مكوّن أو أكثر قد يغير من كيفية استخدام الجسم لبعض المنتجات الطبية مثل<br />سيمڤا.&trade; يجب تجنب استخدام عصير الجريب أثناء العلاج بسيمڤا .&trade;<br /><strong>الحمل و الرضاعة</strong><br />لا تتناولى سيمڤا إذا كنتِ حاملا، تحاولين أن تكونى حاملا أو تشكين أنكِ حاملا. إذا أصبحتى حاملا أثناء العلاج بسيمڤا &trade;.<br />&trade; توقفى عن تناوله فى الحال و اتصلى بطبيبك. لا تتناولى سيمڤا &trade; ،إذا كنتِ مرضعة لأنه من<br />غير المعروف ما إذا كان هذا الدواء ينتقل إلى لبن الثدى أم لا.<br />استشر الطبيب أو الصيدلى قبل أن تتناول أى دواء.<br /><strong>الأطفال</strong><br />لقد تم دراسة فاعلية وأمان&nbsp;سيمڤا&nbsp;&trade; فى الأولاد الذين تبلغ أعمارهم ۱۰- ۱۷ عام و فى البنات الائى بدأ الحيض .<br />عندهن منذ سنة على الأقل ( انظر الجزء ۳ &quot;كيف تتناول سيمڤا)<br />لم يتم دراسة&nbsp;سيمڤا &trade;فى الأطفال الذين يقلون عن ۱۰ سنوات . للمزيد من المعلومات يرجى التحدث مع الطبيب.<br /><strong>قيادة المركبات و تشغيل الآلات</strong><br />من غير المتوقع أن يؤثر&nbsp; سيمڤا فى قدرتك على القيادة أو تشغيل الآلات . بالرغم من ذلك، يجب أن يؤخز فى&nbsp;&nbsp;<br />الإعتبار أن بعض الأشخاص يشعرون بالدوار بعد تناول سميفا&nbsp;.<br /><strong>معلومة هامة عن بعض المكونات الموجودة&nbsp;فى سيمڤا</strong><br />واحد من مكونات أقراص سميفا&trade; ليودبريس يحتوي على اللاكتوز. إذا كان لديك عدم تحمل لبعض أنواع السكر&nbsp;</p><p>تحدث مع طبيبك أو الصيدلي قبل تناول أقراص سيمڤا .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف تتناول سيمڤا&trade;</strong></p><p>قم دائما بتناول سيمڤا&nbsp;&trade; كما أخبرك طبيبك تماما. يجب عليك مراجعة الطبيب أو الصيدلى إذا كنت غير متأكد من طريقة الاستخدام .<br />يجب عليك إتباع نظام غذائى منخفض الكوليستيرول طوال فترة العلاج.<br />الجرعة من سيمڤا&trade; ۱۰ ملجم، ۲۰ ملجم، ٤۰ ملجم أو ۸۰ ملجم يؤخذ عن طريق الفم مرة يوميا.<br />للأطفال ( ۱۰-۱۷ عام) : الجرعة الأولية المعتادة هى ۱۰ ملجم يوميا تؤخذ مساءا. الجرعة القصوى الموصى بها هى ٤۰ ملجم يوميا.-<br />جرعة ۸۰ ملجم يوصى باستخدامها فقط للكبار الذين يعانون من ارتفاع شديد فى مستوى الكوليسترول و ارتفاع<br />خطر الإصابة بأمراض القلب و الذين لم يستطيعوا الوصول إلى مستوى الكوليستيرول المرغوب به باستخدام<br />جرعات أقل.<br />سوف يقوم طبيبك بتحديد الجرعة المناسبة لك تبعا لحالتك ، العلاج الحالى الذى تتناوله و خطورة إصابتك<br />بالأمراض الأخرى.<br />تناول أقراص سيمڤا فى المساء. يمكنك أن تتناولها مع أو بدون الطعام.&nbsp;</p><p>الجرعة الأولية المعتادة هى ۱۰ ملجم، ۲۰ ملجم أو فى بعض الحالات ٤۰ ملجم يوميا.<br />من الممكن أن يقوم طبيبك بتعديل جرعتك بعد ٤ اسابيع على الأقل لتصل إلى حد أقصاه ۸۰ ملجم يوميا. لا<br />تتناول أكثر من ۸۰ ملجم يوميا. قد يصف لك طبيبك جرعات أقل ، خاصة إذا كنت تتناول بعض المنتجات الطبية المذكورة بالأعلى أو إذا كنت تعانى من مشاكل فى الكلى. استمر فى أخذ سيمڤا&nbsp;حتى يخبرك طبيبك بأن تتوقف.<br />إذا قام طبيبك بوصف مستخلبات الحموض الصفراوية (أدوية تستخدم لخفض مستوى الكوليستيرول) بجانب سيمڤا&trade;<br />يجب أن تتناول سيمڤا&trade; ، قبل ساعتين على الأقل من أخذ مستخلبات الحموض الصفراوية أو بعد ٤<br />ساعات من أخذها.<br /><strong>اذا تناولت سيمڤا أكثر مما ينبغى:</strong><br />يرجى استشارة طبيبك أو أقرب مستشفي.<br /><strong>إذا نسيت أن تتناول سيمڤا&trade;:</strong><br />لا تتناول جرعة زائدة لتعويض الجرعة المنسية. تناول جرعتك العادية فى موعدها المعتاد فى اليوم التالى.<br /><strong>إذا توقفت عن تناول سيمڤا&trade;:</strong>&bull;</p><p>قد يرتفع الكولسترول الخاص بك مرة أخرى.<br />إذا كانت لديك أى أسئلة أخرى عن استخدام هذا الدواء، قم بسؤال الطبيب أو الصيدلى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية ، من المحتمل ظهور أعراض جانبية لسيمڤا&nbsp;لكنها لا تصيب كل الأشخاص.</p><p>تستخدم المصطلحات التالية لوصف مدى تكرار حدوث الآثار الجانبية:<br />نادر ( تصيب أكثر من ۱ من كل ۱۰۰۰۰ و أقل من ۱ من كل ۱۰۰۰ شخص يستخدمون هذا الدواء).<br />نادر جدا ( تصيب أقل من ۱ من كل ۱۰۰۰۰ شخص يستخدمون هذا الدواء).<br />مدى الشيوع غير معروف.<br />قد تم الإبلاغ عن الآثار الجانبية النادرة الآتية:<br /><strong>إذا حدث لك أى من الآثار الجانبية الخطيرة الآتية ، توقف عن تناول هذا الدواء وقم باخبار الطبيب على الفور<br />أو اذهب الى قسم الطوارىء بأقرب مستشفى لك.</strong><br />&bull; ألم العضلات، ليونة العضلات أو تشنجات العضلات. فى حالات نادرة ، مشاكل العضلات هذه قد تصبح<br />خطيرة و تؤدى إلى تكسُر العضلات مما يسبب فشل كلوى و فى بعض الحالات النادرة جدا يؤدى الى الوفاة.<br />&bull; تفاعلات فرط الحساسية و التى تشمل: تورم الوجه، اللسان و الحلق مما يسبب صعوبة فى التنفس.<br />&bull; ألم شديد فى العضلات عادة ما يكون فى الكتفين و الفخذين.<br />&bull; طفح جلدى مع ضعف فى الأطراف و عضلات الرقبة.<br />&bull; ألم و التهاب فى المفاصل.<br />&bull; التهاب فى الأوعية الدموية.<br />&bull; كدمات غير عادية، طفح جلدى، تورم الجلد، يصبح الجلد حساس لآشعة الشمس، حمى، هبات ساخنة.<br />&bull; ضيق فى التنفس، الشعور بالتعب.<br />&bull; أعراض تشبه أعراض مرض الذئبة ( طفح جلدى، مشاكل المفاصل و تغيرات فى خلايا الدم).<br />&bull; التهاب الكبد المؤدى الى اصفرار الجلد و العينين، حكة، بول داكن اللون أو براز شاحب اللون ، فشل كبدى و<br />هى حالة نادرة الحدوث جدا.<br />&bull; التهاب البنكرياس غالبا ما يصاحبه ألم شديد فى البطن.<br />الأعراض الجانبية التالية قد تم الإبلاغ عنها أيضا بصورة نادرة:<br />&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم).<br />&bull; تنميل أو ضعف فى اليدين و القدمين.<br />&bull; صداع ، الشعور بالوخز، دوار.<br />&bull; اضطرابات فى الجهاز الهضمى (ألم فى البطن، إمساك، انتفاخ البطن، عسر الهضم، إسهال، غثيان و قىء).<br />&bull; طفح جلدى، حكة، فقدان الشعر.<br />&bull; ضعف.<br />&bull; إضطرابات النوم (نادرجدا).<br />&bull; ضعف الذاكرة (نادر جدا).<br />تم الإبلاغ عن الآثار الجانبية التالية لكن مدى تكرار حدوثها لا يمكن أن يحدد من المعلومات المتاحة (مدى<br />الشيوع غير معروف):<br />&bull; ضعف الإنتصاب.<br />&bull; إكتئاب.<br />&bull; التهاب الرئتين مما يسبب مشاكل فى التنفس تشمل: سعال مستمر و/ أو ضيق فى التنفس أو حمى .<br />&bull; مشاكل فى الأوتار تتعقد أحيانا لتصل إلى تمزق الأوتار.<br />الآثار الجانبية الأخرى التى تم الإبلاغ عنها مع بعض &quot;الستاتينات&quot;:<br />&bull; إضطرابات النوم و الكوابيس.<br />&bull; ضعف الذاكرة.<br />&bull; صعوبات جنسية.<br />&bull; داء السكرى. يكون هذا أكثر حدوثا إذا كانت مستويات السكر و الدهون مرتفعة فى دمك ، تعانى من زيادة<br />الوزن و لديك ارتفاع فى ضغط الدم. سوف يقوم طبيبك بمتابعتك أثناء تلقيك هذا الدواء.<br /><strong>القيم المعملية</strong><br />قد لوحظ حدوث ارتفاع فى قيم بعض فحوصات الدم المعملية لوظائف الكبد و انزيم العضلات (كيناز<br />الكرياتينين).<br />&quot;وكانت هناك تقارير نادرة بعد التسويق للضعف الادراكي مرتبط بإستخدام الستاتينات (على سبيل المثال، فقدان<br />الذاكرة، نسيان، ضعف الذاكرة؛ الارتباك). و قد تم تسجيل هذه المسائل الادراكية لجميع الستاتينات وفي<br />التقارير عادة ما تكون غير خطيرة، وإنعكاسية مع وقف الستاتين، مع أوقات متغيرة لظهور الأعراض ( ۱ يوم<br />إلى سنة) و زوال الأعراض (المتوسط ۳ أسابيع).<br />يرجى اخبار الطبيب أو الصيدلى إذا أصبحت إحدى الأعراض الجانبية خطيرة أو لاحظت حدوث أية أعراض<br />جانبيٮة أخرى غير المذكورة فى هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول و مرأى الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تتناول أقراص سيمڤا&trade; بعد انتهاء فترة صلاحيتها المكتوب على العلبة.<br />قم دائما بحفظ الشرائط داخل العلبة الخارجية لتحميها من الرطوبة.<br />اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر إلقائها<br />فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مادة الفعالة هى سيمڤاستاتين ( ۱۰ ملجم، ۲۰ ملجم أو ٤۰ ملجم).<br />المواد الأخرى هى: بيوتيلاتد هيدروكسيل انيسول، حمض الستريك مونوهيدرات، كروسكارميلوزالصوديوم ،<br />كروسبوفيدون، هيدروكسي بروبيل السليلوز، ليودبريس، ستيرات المغنيسيوم، ميكرو كريستلين سليلوز ،<br />أوبادرى أبيض، بولي سوربات ۸۰ ، بوفيدون، نشا مسبق التجلتن، بروبيلين جليكول، ثاني أكسيد السيليكون<br />الغروي، سيميثيكون، التلك، وماء منقي</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><br />۱۰ ملجم لونها أبيض إلي مائل للبياض ، بيضاوية ، ثنائية التحدب مغلفة ، محفورة على جانب واحد `JP33` أقراص سيمڤا<br />ومستوية في الجانب الآخر.&nbsp;<br />۲۰ ملجم لونها أبيض إلي مائل للبياض ، بيضاوية ، ثنائية التحدب مغلفة ، محفورة على جانب واحد&nbsp; `JP34` أقراص سيمڤا<br />ومستوية في الجانب الآخر.<br />٤۰ ملجم لونها أبيض إلي مائل للبياض ، دائرية ، ثنائية التحدب مغلفة ، محفورة على جانب واحد `JP35` قراص سيمڤا<br />ومستوية في الجانب الآخر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/jpeg;base64,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" alt="" width="602" height="360" vspace="0" hspace="0" border="0" style="width:602px;height:360px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02-2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Simva 10mg Film coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg of simvastatin.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White to off white, oval biconvex film coated tablets, engraved with 'JP33' on one side and slain on the other
side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Hypercholesterolaemia</strong></u><br />Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to<br />diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.<br />Treatment of homozygous familial hypercholesterolaemia (HoFH) as an adjunct to diet and other lipidlowering<br />treatments (e.g. LDL apheresis) or if such treatments are not appropriate.<br /><u><strong>Cardiovascular prevention</strong></u><br />Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular<br />disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of<br />other risk factors and other cardioprotective therapy (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Posology</strong></u><br />The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of dosage, if<br />required, should be made at intervals of not less than 4 weeks, to a maximum of 80 mg/day given as a single<br />dose in the evening. The 80-mg dose is only recommended in patients with severe hypercholesterolaemia and<br />at high risk for cardiovascular complications who have not achieved their treatment goals on lower doses and<br />when the benefits are expected to outweigh the potential risks (see sections 4.4 and 5.1).<br />&nbsp;</p><p><em>Hypercholesterolaemia</em><br />The patient should be placed on a standard cholesterol-lowering diet, and should continue on this diet during<br />treatment with Simva. The usual starting dose is 10-20 mg/day given as a single dose in the evening. Patients&nbsp;who require a large reduction in LDL-C (more than 45 %) may be started at 20-40 mg/day given as a single<br />dose in the evening. Adjustments of dosage, if required, should be made as specified above.<br />&nbsp;</p><p><em>Homozygous familial hypercholesterolaemia</em><br />Based on the results of a controlled clinical study, the recommended starting dosage is Simva 40 mg/day in the<br />evening. Simva should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these<br />patients or if such treatments are unavailable.<br />In patients taking lomitapide concomitantly with Simvad, the dose of Simva must not exceed 40 mg/day (see<br />sections 4.3, 4.4 and 4.5).</p><p><br /><em>Cardiovascular prevention</em><br />The usual dose of Simva is 20 to 40 mg/day given as a single dose in the evening in patients at high risk of<br />coronary heart disease (CHD, with or without hyperlipidaemia). Drug therapy can be initiated simultaneously<br />with diet and exercise. Adjustments of dosage, if required, should be made as specified above.</p><p><em><u>Concomitant therapy</u></em><br />Simva is effective alone or in combination with bile acid sequestrants. Dosing should occur either &gt; 2 hours<br />before or &gt; 4 hours after administration of a bile acid sequestrant.<br />In patients taking Simva concomitantly with fibrates, other than gemfibrozil (see section 4.3) or fenofibrate,<br />the dose of Simva should not exceed 10 mg/day. In patients taking amiodarone, amlodipine, verapamil, or<br />diltiazem concomitantly with Simva, the dose of Simva should not exceed 20 mg/day. (See sections 4.4 and<br />4.5.)<br /><em>Patients with renal impairment</em><br />No modification of dosage should be necessary in patients with moderate renal impairment.<br />In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min), dosages above 10 mg/day should<br />be carefully considered and, if deemed necessary, implemented cautiously.<br />&nbsp;</p><p><em>Older people</em><br />No dosage adjustment is necessary.</p><p><u><em>Paediatric population</em></u><br />For children and adolescents (boys Tanner Stage II and above and girls who are at least one year postmenarche,<br />10-17 years of age) with heterozygous familial hypercholesterolaemia, the recommended usual<br />starting dose is 10 mg once a day in the evening. Children and adolescents should be placed on a standard<br />cholesterol-lowering diet before simvastatin treatment initiation; this diet should be continued during<br />simvastatin treatment.<br />The recommended dosing range is 10-40 mg/day; the maximum recommended dose is 40 mg/day. Doses<br />should be individualized according to the recommended goal of therapy as recommended by the paediatric<br />treatment recommendations (see sections 4.4 and 5.1). Adjustments should be made at intervals of 4 weeks or<br />more.<br />The experience of Simva in pre-pubertal children is limited.<br /><u><strong>Method of administration</strong></u></p><p><br />Simva is for oral administration. Simva can be administered as a single dose in the evening.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Active liver disease or unexplained persistent elevations of serum transaminases
• Pregnancy and lactation (see section 4.6)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC approximately 5 fold or
greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors (e.g. nelfinavir),
boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and medicinal products
containing cobicistat) (see sections 4.4 and 4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5).
• In patients with HoFH, concomitant administration of lomitapide with doses > 40 mg Simva (see sections
4.2, 4.4 and 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myopathy/Rhabdomyolysis</u></p><p><br />Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle<br />pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN).<br />Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to<br />myoglobinuria, and very rare fatalities have occurred. The risk of myopathy is increased by high levels of<br />HMG-CoA reductase inhibitory activity in plasma.</p><p>As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is dose related. In a<br />clinical trial database in which 41,413 patients were treated with Simva, 24,747 (approximately 60 %) of<br />whom were enrolled in studies with a median follow-up of at least 4 years, the incidence of myopathy was<br />approximately 0.03 %, 0.08 % and 0.61 % at 20, 40 and 80 mg/day, respectively. In these trials, patients were<br />carefully monitored and some interacting medicinal products were excluded.<br />In a clinical trial in which patients with a history of myocardial infarction were treated with Simva 80 mg/day<br />(mean follow-up 6.7 years), the incidence of myopathy was approximately 1.0 % compared with 0.02 % for<br />patients on 20 mg/day. Approximately half of these myopathy cases occurred during the first year of treatment.<br />The incidence of myopathy during each subsequent year of treatment was approximately 0.1 %. (See sections<br />4.8 and 5.1.)<br />The risk of myopathy is greater in patients on simvastatin 80 mg compared with other statin-based therapies<br />with similar LDL-C-lowering efficacy. Therefore, the 80-mg dose of Simva should only be used in patients<br />with severe hypercholesterolemia and at high risk for cardiovascular complications who have not achieved<br />their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks. In<br />patients taking simvastatin 80 mg for whom an interacting agent is needed, a lower dose of simvastatin or an<br />alternative statin-based regimen with less potential for drug-drug interactions should be used (see below<br />Measures to reduce the risk of myopathy caused by medicinal product interactions and sections 4.2, 4.3, and<br />4.5).<br />In a clinical trial in which patients at high risk of cardiovascular disease were treated with simvastatin 40<br />mg/day (median follow-up 3.9 years), the incidence of myopathy was approximately 0.05 % for non-Chinese<br />patients (n = 7367) compared with 0.24 % for Chinese patients (n = 5468). While the only Asian population<br />assessed in this clinical trial was Chinese, caution should be used when prescribing simvastatin to Asian<br />patients and the lowest dose necessary should be employed.</p><p><br /><strong><em>Reduced function of transport proteins</em></strong><br />Reduced function of hepatic OATP transport proteins can increase the systemic exposure of simvastatin acid<br />and increase the risk of myopathy and rhabdomyolysis. Reduced function can occur as the result of inhibition<br />by interacting medicines (eg ciclosporin) or in patients who are carriers of the SLCO1B1 c.521T&gt;C genotype.<br />Patients carrying the SLCO1B1 gene allele (c.521T&gt;C) coding for a less active OATP1B1 protein have an<br />increased systemic exposure of simvastatin acid and increased risk of myopathy. The risk of high dose (80 mg)<br />simvastatin related myopathy is about 1% in general, without genetic testing. Based on the results of the<br />SEARCH trial, homozygote C allele carriers (also called CC) treated with 80 mg have a 15% risk of myopathy<br />within one year, while the risk in heterozygote C allele carriers (CT) is 1.5%. The corresponding risk is 0.3%<br />in patients having the most common genotype (TT) (See section 5.2). Where available, genotyping for the<br />presence of the C allele should be considered as part of the benefit-risk assessment prior to prescribing 80 mg<br />simvastatin for individual patients and high doses avoided in those found to carry the CC genotype. However,<br />absence of this gene upon genotyping does not exclude that myopathy can still occur.</p><p><em><strong>Creatine Kinase measurement</strong></em><br />Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of any plausible<br />alternative cause of CK increase as this makes value interpretation difficult. If CK levels are significantly<br />elevated at baseline (&gt; 5 x ULN), levels should be re-measured within 5 to 7 days later to confirm the results.<br /><em><strong>Before the treatment</strong></em><br />All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, should be<br />advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or<br />weakness.<br />Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis. In order to establish a<br />reference baseline value, a CK level should be measured before starting a treatment in the following situations:<br />&bull; Elderly (age &ge; 65 years)<br />&bull; Female gender<br />&bull; Renal impairment<br />&bull; Uncontrolled hypothyroidism<br />&bull; Personal or familial history of hereditary muscular disorders<br />&bull; Previous history of muscular toxicity with a statin or fibrate<br />&bull; Alcohol abuse.</p><p>In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical<br />monitoring is recommended. If a patient has previously experienced a muscle disorder on a fibrate or a statin,<br />treatment with a different member of the class should only be initiated with caution. If CK levels are<br />significantly elevated at baseline (&gt; 5 x ULN), treatment should not be started.<br /><strong><em>Whilst on treatment</em></strong><br />If muscle pain, weakness or cramps occur whilst a patient is receiving treatment with a statin, their CK levels<br />should be measured. If these levels are found, in the absence of strenuous exercise, to be significantly elevated<br />(&gt; 5 x ULN), treatment should be stopped. If muscular symptoms are severe and cause daily discomfort, even<br />if CK levels are &lt; 5 x ULN, treatment discontinuation may be considered. If myopathy is suspected for any<br />other reason, treatment should be discontinued.</p><p>There have been very rare reports of an immune-mediated necrotizing myopathy (IMNM) during or after<br />treatment with some statins. IMNM is clinically characterized by persistent proximal muscle weakness and<br />elevated serum creatine kinase, which persist despite discontinuation of statin treatment (see section 4.8).<br />If symptoms resolve and CK levels return to normal, then re-introduction of the statin or introduction of an<br />alternative statin may be considered at the lowest dose and with close monitoring.<br />A higher rate of myopathy has been observed in patients titrated to the 80 mg dose (see section 5.1). Periodic<br />CK measurements are recommended as they may be useful to identify subclinical cases of myopathy.<br />However, there is no assurance that such monitoring will prevent myopathy.<br />Therapy with simvastatin should be temporarily stopped a few days prior to elective major surgery and when<br />any major medical or surgical condition supervenes.<br /><em><strong>Measures to reduce the risk of myopathy caused by medicinal product interactions (see also section 4.5)</strong></em><br />The risk of myopathy and rhabdomyolysis is significantly increased by concomitant use of simvastatin with<br />potent inhibitors of CYP3A4 (such as itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin,<br />clarithromycin, telithromycin, HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, nefazodone,<br />medicinal products containing cobicistat), as well as gemfibrozil, ciclosporin, and danazol. Use of these<br />medicinal products is contraindicated (see section 4.3).<br />The risk of myopathy and rhabdomyolysis is also increased by concomitant use of amiodarone, amlodipine,<br />verapamil, or diltiazem with certain doses of simvastatin (see sections 4.2 and 4.5). The risk of myopathy,<br />including rhabdomyolysis, may be increased by concomitant administration of fusidic acid with statins (see<br />section 4.5). For patients with HoFH, this risk may be increased by concomitant use of lomitapide with<br />simvastatin.</p><p>Consequently, regarding CYP3A4 inhibitors, the use of simvastatin concomitantly with itraconazole,<br />ketoconazole, posaconazole, voriconazole, HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir,<br />erythromycin, clarithromycin, telithromycin, nefazodone, and medicinal products containing cobicistat is<br />contraindicated (see sections 4.3 and 4.5). If treatment with potent CYP3A4 inhibitors (agents that increase<br />AUC approximately 5 fold or greater) is unavoidable, therapy with simvastatin must be suspended (and use of<br />an alternative statin considered) during the course of treatment. Moreover, caution should be exercised when<br />combining simvastatin with certain other less potent CYP3A4 inhibitors: fluconazole, verapamil, diltiazem<br />(see sections 4.2 and 4.5). Concomitant intake of grapefruit juice and simvastatin should be avoided.<br />The use of simvastatin with gemfibrozil is contraindicated (see section 4.3). Due to the increased risk of<br />myopathy and rhabdomyolysis, the dose of simvastatin should not exceed 10 mg daily in patients taking<br />simvastatin with other fibrates, except fenofibrate. (See sections 4.2 and 4.5.) Caution should be used when<br />prescribing fenofibrate with simvastatin, as either agent can cause myopathy when given alone.</p><p>Simvastatin must not be co-administered with fusidic acid. There have been reports of rhabdomyolysis<br />(including some fatalities) in patients receiving this combination (see section 4.5). In patients where the use of<br />systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of<br />fusidic acid treatment. The patient should be advised to seek medical advice immediately if they experience<br />any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after<br />the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed,<br />e.g., for the treatment of severe infections, the need for co-administration of simvastatin and fusidic acid<br />should only be considered on a case by case basis and under close medical supervision.<br />The combined use of simvastatin at doses higher than 20 mg daily with amiodarone, amlodipine, verapamil, or<br />diltiazem should be avoided. In patients with HoFH, the combined use of simvastatin at doses higher than 40<br />mg daily with lomitapide must be avoided. (See sections 4.2, 4.3 and 4.5).<br />Patients taking other medicines labelled as having a moderate inhibitory effect on CYP3A4 concomitantly with<br />simvastatin, particularly higher simvastatin doses, may have an increased risk of myopathy. When<br />coadministering simvastatin with a moderate inhibitor of CYP3A4 (agents that increase AUC approximately 2-<br />5 fold), a dose adjustment of simvastatin may be necessary. For certain moderate CYP3A4 inhibitors e.g.<br />diltiazem, a maximum dose of 20mg simvastatin is recommended (see section 4.2)<br />Rare cases of myopathy/rhabdomyolysis have been associated with concomitant administration of HMG-CoA<br />reductase inhibitors and lipid-modifying doses (&ge; 1 g/day) of niacin (nicotinic acid), either of which can cause<br />myopathy when given alone.<br />In a clinical trial (median follow-up 3.9 years) involving patients at high risk of cardiovascular disease and<br />with well-controlled LDL-C levels on simvastatin 40 mg/day with or without ezetimibe 10 mg, there was no<br />incremental benefit on cardiovascular outcomes with the addition of lipid-modifying doses (&ge;1 g/day) of niacin<br />(nicotinic acid). Therefore, physicians contemplating combined therapy with simvastatin and lipid-modifying<br />doses (&ge; 1 g/day) of niacin (nicotinic acid) or products containing niacin should carefully weigh the potential<br />benefits and risks and should carefully monitor patients for any signs and symptoms of muscle pain,<br />tenderness, or weakness, particularly during the initial months of therapy and when the dose of either<br />medicinal product is increased.</p><p>In addition, in this trial, the incidence of myopathy was approximately 0.24 % for Chinese patients on<br />simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg compared with 1.24 % for Chinese patients on<br />simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg coadministered with modified-release nicotinic<br />acid/laropiprant 2000 mg/40 mg. While the only Asian population assessed in this clinical trial was Chinese,<br />because the incidence of myopathy is higher in Chinese than in non-Chinese patients, coadministration of<br />simvastatin with lipid-modifying doses (&ge;1 g/day) of niacin (nicotinic acid) is not recommended in Asian<br />patients.<br />Acipimox is structurally related to niacin. Although acipimox was not studied, the risk for muscle related toxic<br />effects may be similar to niacin.</p><p><u><strong>Hepatic effects</strong></u><br />In clinical studies, persistent increases (to &gt; 3 x ULN) in serum transaminases have occurred in a few adult<br />patients who received simvastatin. When simvastatin was interrupted or discontinued in these patients, the<br />transaminase levels usually fell slowly to pre-treatment levels.<br />It is recommended that liver function tests be performed before treatment begins and thereafter when clinically<br />indicated. Patients titrated to the 80-mg dose should receive an additional test prior to titration, 3 months after<br />titration to the 80-mg dose, and periodically thereafter (e.g., semi-annually) for the first year of treatment.<br />Special attention should be paid to patients who develop elevated serum transaminase levels, and in these<br />patients, measurements should be repeated promptly and then performed more frequently. If the transaminase<br />levels show evidence of progression, particularly if they rise to 3 x ULN and are persistent, simvastatin should<br />be discontinued. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate<br />myopathy (see above Myopathy/Rhabdomyolysis).<br />There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins,<br />including simvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinaemia or jaundice<br />occurs during treatment with Simva, promptly interrupt therapy. If an alternate etiology is not found, do not<br />restart Simva.<br />The product should be used with caution in patients who consume substantial quantities of alcohol.</p><p>As with other lipid-lowering agents, moderate (&lt; 3 x ULN) elevations of serum transaminases have been<br />reported following therapy with simvastatin. These changes appeared soon after initiation of therapy with<br />simvastatin, were often transient, were not accompanied by any symptoms and interruption of treatment was<br />not required.<br /><strong><u>Diabetes mellitus</u></strong><br />Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future<br />diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however,<br />is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping<br />statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI &gt; 30 kg/m2, raised triglycerides,<br />hypertension) should be monitored both clinically and biochemically according to national guidelines.<br /><u><strong>Interstitial lung disease</strong></u><br />Cases of interstitial lung disease have been reported with some statins, including simvastatin, especially with<br />long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and<br />deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed<br />interstitial lung disease, statin therapy should be discontinued.</p><p><u><strong>Paediatric population</strong></u><br />Safety and effectiveness of simvastatin in patients 10-17 years of age with heterozygous familial<br />hypercholesterolaemia have been evaluated in a controlled clinical trial in adolescent boys Tanner Stage II and<br />above and in girls who were at least one year post-menarche. Patients treated with simvastatin had an adverse<br />experience profile generally similar to that of patients treated with placebo. Doses greater than 40 mg have<br />not been studied in this population. In this limited controlled study, there was no detectable effect on growth<br />or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls. (See<br />sections 4.2, 4.8, and 5.1). Adolescent females should be counselled on appropriate contraceptive methods<br />while on simvastatin therapy (see sections 4.3 and 4.6). In patients aged &lt; 18 years, efficacy and safety have<br />not been studied for treatment periods &gt; 48 weeks&#39; duration and long-term effects on physical, intellectual, and<br />sexual maturation are unknown. Simvastatin has not been studied in patients younger than 10 years of age, nor<br />in pre-pubertal children and pre-menarchal girls.<br /><u><strong>Excipient</strong></u><br />This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase<br />deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.<br /><u><strong>Pharmacodynamic interactions</strong></u><br />Interactions with lipid-lowering medicinal products that can cause myopathy when given alone<br />The risk of myopathy, including rhabdomyolysis, is increased during concomitant administration with fibrates.<br />Additionally, there is a pharmacokinetic interaction with gemfibrozil resulting in increased simvastatin plasma<br />levels (see below Pharmacokinetic interactions and sections 4.3 and 4.4). When simvastatin and fenofibrate<br />are given concomitantly, there is no evidence that the risk of myopathy exceeds the sum of the individual risks<br />of each agent. Adequate pharmacovigilance and pharmacokinetic data are not available for other fibrates. Rare<br />cases of myopathy/rhabdomyolysis have been associated with simvastatin co-administered with lipidmodifying<br />doses (&ge; 1 g/day) of niacin (see section 4.4).</p><p><u><strong>Pharmacokinetic interactions</strong></u><br />Prescribing recommendations for interacting agents are summarized in the table below (further details are<br />provided in the text; see also sections 4.2, 4.3, and 4.4).<br />Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis</p><p>&nbsp;</p><p><img alt="" width="785" height="941" src="data:image/png;base64,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" /><strong><em>Effects of other medicinal products on simvastatin</em></strong><br /><strong><em>Interactions involving inhibitors of CYP3A4</em></strong><br />Simvastatin is a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome P450 3A4 increase the<br />risk of myopathy and rhabdomyolysis by increasing the concentration of HMG-CoA reductase inhibitory<br />activity in plasma during simvastatin therapy. Such inhibitors include itraconazole, ketoconazole,<br />posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors (e.g.<br />nelfinavir), boceprevir, telaprevir, nefazodone and medicinal products containing cobicistat. Concomitant<br />administration of itraconazole resulted in a more than 10-fold increase in exposure to simvastatin acid (the<br />active beta-hydroxyacid metabolite). Telithromycin caused an 11-fold increase in exposure to simvastatin acid.<br />Combination with itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors (e.g.<br />nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and medicinal<br />products containing cobicistat is contraindicated, as well as gemfibrozil, ciclosporin, and danazol (see section<br />4.3). If treatment with potent CYP3A4 inhibitors (agents that increase AUC approximately 5 fold or greater) is<br />unavoidable, therapy with simvastatin must be suspended (and use of an alternative statin considered) during<br />the course of treatment. Caution should be exercised when combining simvastatin with certain other less potent<br />CYP3A4 inhibitors: fluconazole, verapamil, or diltiazem (see sections 4.2 and 4.4).</p><p><br /><strong><em>Fluconazole</em></strong><br />Rare cases of rhabdomyolysis associated with concomitant administration of simvastatin and fluconazole have<br />been reported (see section 4.4).<br /><em><strong>Ciclosporin</strong></em><br />The risk of myopathy/rhabdomyolysis is increased by concomitant administration of ciclosporin with<br />simvastatin; therefore, use with ciclosporin is contraindicated (see sections 4.3 and 4.4). Although the<br />mechanism is not fully understood, ciclosporin has been shown to increase the AUC of HMG-CoA reductase<br />inhibitors. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4<br />and/or OATP1B1.</p><p><strong><em>Danazol</em></strong><br />The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with<br />simvastatin; therefore, use with danazol is contraindicated. (see sections 4.3 and 4.4).<br /><strong><em>Gemfibrozil</em></strong><br />Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of the<br />glucuronidation pathway and/or OATP1B1 (see sections 4.3 and 4.4). Concomitant administration with<br />gemfibrozil is contraindicated.<br /><em><strong>Fusidic acid</strong></em><br />The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of<br />systemic fusidic acid with statins. Co-administration of this combination may cause increased plasma<br />concentrations of both agents. The mechanism of this interaction (whether it is pharmacodynamics or<br />pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some<br />fatalities) in patients receiving this combination. If treatment with fusidic acid is necessary, simvastatin<br />treatment should be discontinued throughout the duration of the fusidic acid treatment. (See section 4.4.) .</p><p><br /><strong><em>Amiodarone</em></strong><br />The risk of myopathy and rhabdomyolysis is increased by concomitant administration of amiodarone with<br />simvastatin (see section 4.4). In a clinical trial, myopathy was reported in 6 % of patients receiving simvastatin<br />80 mg and amiodarone. Therefore, the dose of simvastatin should not exceed 20 mg daily in patients receiving<br />concomitant medication with amiodarone.<br /><strong><em>Calcium Channel Blockers<br />&bull; Verapamil</em></strong></p><p>The risk of myopathy and rhabdomyolysis is increased by concomitant administration of verapamil with<br />simvastatin 40 mg or 80 mg (see section 4.4). In a pharmacokinetic study, concomitant administration with<br />verapamil resulted in a 2.3-fold increase in exposure of simvastatin acid, presumably due, in part, to inhibition<br />of CYP3A4. Therefore, the dose of simvastatin should not exceed 20 mg daily in patients receiving<br />concomitant medication with verapamil.<br /><em><strong>&bull; Diltiazem</strong></em><br />The risk of myopathy and rhabdomyolysis is increased by concomitant administration of diltiazem with<br />simvastatin 80 mg (see section 4.4). In a pharmacokinetic study, concomitant administration of diltiazem<br />caused a 2.7-fold increase in exposure of simvastatin acid, presumably due to inhibition of CYP3A4.</p><p>Therefore, the dose of simvastatin should not exceed 20 mg daily in patients receiving concomitant medication<br />with diltiazem.<br /><em><strong>&bull; Amlodipine</strong></em><br />Patients on amlodipine treated concomitantly with simvastatin have an increased risk of myopathy. In a<br />pharmacokinetic study, concomitant administration of amlodipine caused a 1.6-fold increase in exposure of<br />simvastatin acid. Therefore, the dose of simvastatin should not exceed 20 mg daily in patients receiving<br />concomitant medication with amlodipine.<br /><em><strong>Lomitapide</strong></em><br />The risk of myopathy and rhabdomyolysis may be increased by concomitant administration of lomitapide with<br />simvastatin (see sections 4.3 and 4.4). Therefore, in patients with HoFH, the dose of simvastatin must not<br />exceed 40 mg daily in patients receiving concomitant medication with lomitapide.<br /><em><strong>Moderate Inhibitors of CYP3A4</strong></em><br />Patients taking other medicines labelled as having a moderate inhibitory effect on CYP3A4 concomitantly with<br />simvastatin, particularly higher simvastatin doses, may have an increased risk of myopathy (see section 4.4).</p><p><em><strong>Inhibitors of the Transport Protein OATP1B1</strong></em><br />Simvastatin acid is a substrate of the transport protein OATP1B1. Concomitant administration of medicinal<br />products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of<br />simvastatin acid and an increased risk of myopathy (see sections 4.3 and 4.4).<br /><em><strong>Niacin (nicotinic acid)</strong></em><br />Rare cases of myopathy/rhabdomyolysis have been associated with simvastatin co-administered with lipidmodifying<br />doses (&ge; 1 g/day) of niacin (nicotinic acid). In a pharmacokinetic study, the co-administration of a<br />single dose of nicotinic acid prolonged-release 2 g with simvastatin 20 mg resulted in a modest increase in the<br />AUC of simvastatin and simvastatin acid and in the Cmax of simvastatin acid plasma concentrations.<br /><em><strong>Grapefruit juice</strong></em><br />Grapefruit juice inhibits cytochrome P450 3A4. Concomitant intake of large quantities (over 1 litre daily) of<br />grapefruit juice and simvastatin resulted in a 7-fold increase in exposure to simvastatin acid. Intake of 240 ml<br />of grapefruit juice in the morning and simvastatin in the evening also resulted in a 1.9-fold increase. Intake of<br />grapefruit juice during treatment with simvastatin should therefore be avoided.</p><p><em><strong>Colchicine</strong></em><br />There have been reports of myopathy and rhabdomyolysis with the concomitant administration of colchicine<br />and simvastatin in patients with renal impairment. Close clinical monitoring of such patients taking this<br />combination is advised.<br /><em><strong>Rifampicin</strong></em><br />Because rifampicin is a potent CYP3A4 inducer, patients undertaking long-term rifampicin therapy (e.g.<br />treatment of tuberculosis) may experience loss of efficacy of simvastatin. In a pharmacokinetic study in normal<br />volunteers, the area under the plasma concentration curve (AUC) for simvastatin acid was decreased by 93%<br />with concomitant administration of rifampicin.<br /><em><strong>Effects of simvastatin on the pharmacokinetics of other medicinal products</strong></em><br />Simvastatin does not have an inhibitory effect on cytochrome P450 3A4. Therefore, simvastatin is not<br />expected to affect plasma concentrations of substances metabolised via cytochrome P450 3A4.<br /><em><strong>Oral anticoagulants</strong></em><br />In two clinical studies, one in normal volunteers and the other in hypercholesterolaemic patients, simvastatin<br />20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as<br />International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the<br />volunteer and patient studies, respectively. Very rare cases of elevated INR have been reported. In patients<br />taking coumarin anticoagulants, prothrombin time should be determined before starting simvastatin and<br />frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.<br />Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals<br />usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or<br />discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with<br />bleeding or with changes in prothrombin time in patients not taking anticoagulants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong><br />Simva is contraindicated during pregnancy (see section 4.3).<br />Safety in pregnant women has not been established. No controlled clinical trials with simvastatin have been<br />conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMGCoA<br />reductase inhibitors have been received. However, in an analysis of approximately 200 prospectively<br />followed pregnancies exposed during the first trimester to Simva or another closely related HMG-CoA<br />reductase inhibitor, the incidence of congenital anomalies was comparable to that seen in the general&nbsp;population. This number of pregnancies was statistically sufficient to exclude a 2.5-fold or greater increase in<br />congenital anomalies over the background incidence.<br />Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking Simva<br />or another closely related HMG-CoA reductase inhibitor differs from that observed in the general population,<br />maternal treatment with Simva may reduce the foetal levels of mevalonate which is a precursor of cholesterol<br />biosynthesis. Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering medicinal<br />products during pregnancy should have little impact on the long-term risk associated with primary<br />hypercholesterolaemia. For these reasons, Simva must not be used in women who are pregnant, trying to<br />become pregnant or suspect they are pregnant. Treatment with Simva must be suspended for the duration of<br />pregnancy or until it has been determined that the woman is not pregnant. (See sections 4.3 and 5.3.)<br /><u><strong>Breast-feeding</strong></u><br />It is not known whether simvastatin or its metabolites are excreted in human milk. Because many medicinal<br />products are excreted in human milk and because of the potential for serious adverse reactions, women taking<br />Simva must not breast-feed their infants (see section 4.3).<br /><u><strong>Fertility</strong></u><br />No clinical trial data are available on the effects of simvastatin on human fertility. Simvastatin had no effect on<br />the fertility of male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simva has no or negligible influence on the ability to drive and use machines. However, when driving vehicles<br />or operating machines, it should be taken into account that dizziness has been reported rarely in post-marketing<br />experiences.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequencies of the following adverse events, which have been reported during clinical studies and/or postmarketing<br />use, are categorized based on an assessment of their incidence rates in large, long-term, placebocontrolled,<br />clinical trials including HPS and 4S with 20,536 and 4,444 patients, respectively (see section 5.1).<br />For HPS, only serious adverse events were recorded as well as myalgia, increases in serum transaminases and<br />CK. For 4S, all the adverse events listed below were recorded. If the incidence rates on simvastatin were less<br />than or similar to that of placebo in these trials, and there were similar reasonably causally related spontaneous<br />report events, these adverse events are categorized as &ldquo;rare&rdquo;.<br />In HPS (see section 5.1) involving 20,536 patients treated with 40 mg/day of Simva (n = 10,269) or placebo (n<br />= 10,267), the safety profiles were comparable between patients treated with Simva 40 mg and patients treated</p><p>with placebo over the mean 5 years of the study. Discontinuation rates due to side effects were comparable<br />(4.8 % in patients treated with Simva 40 mg compared with 5.1 % in patients treated with placebo). The<br />incidence of myopathy was &lt; 0.1 % in patients treated with Simva 40 mg. Elevated transaminases (&gt; 3 x ULN<br />confirmed by repeat test) occurred in 0.21 % (n = 21) of patients treated with Simva 40 mg compared with<br />0.09 % (n = 9) of patients treated with placebo.<br />The frequencies of adverse events are ranked according to the following: Very common (&gt; 1/10), Common (&ge;<br />1/100, &lt; 1/10), Uncommon (&ge; 1/1000, &lt; 1/100), Rare (&ge; 1/10,000, &lt; 1/1000), Very Rare (&lt; 1/10,000), not<br />known (cannot be estimated from the available data).<br /><strong><u>Blood and lymphatic system disorders:</u></strong><br />Rare: anaemia<br /><u><strong>Psychiatric disorders:</strong></u><br />Very rare: insomnia<br />Not known: depression<br /><u><strong>Nervous system disorders</strong></u>:<br />Rare: headache, paresthesia, dizziness, peripheral neuropathy<br />Very rare: memory impairment<br /><u><strong>Respiratory, thoracic and mediastinal disorders:</strong></u><br />Not known: interstitial lung disease (see section 4.4)<br /><u><strong>Gastrointestinal disorders:</strong></u><br />Rare: constipation, abdominal pain, flatulence, dyspepsia, diarrhoea, nausea, vomiting, pancreatitis<br /><u><strong>Hepatobiliary disorders:</strong></u><br />Rare: hepatitis/jaundice<br />Very rare: fatal and non-fatal hepatic failure</p><p><u><strong>Skin and subcutaneous tissue disorders:</strong></u><br />Rare: rash, pruritus, alopecia<br /><u><strong>Musculoskeletal and connective tissue disorders:</strong></u><br />Rare: myopathy* (including myositis), rhabdomyolysis with or without acute renal failure (see section 4.4),<br />myalgia, muscle cramps<br />* In a clinical trial, myopathy occurred commonly in patients treated with Simva 80 mg/day compared to<br />patients treated with 20 mg/day (1.0 % vs 0.02 %, respectively) (see sections 4.4 and 4.5).<br />Not known: tendinopathy, sometimes complicated by rupture; immune-mediated necrotizing myopathy<br />(IMNM)**<br />** There have been very rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune<br />myopathy, during or after treatment with some statins. IMNM is clinically characterized by: persistent<br />proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin<br />treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with<br />immunosuppressive agents (see section 4.4).<br /><u><strong>Reproductive system and breast disorders:</strong></u><br />Not known: erectile dysfunction<br /><u><strong>General disorders and administration site conditions:</strong></u><br />Rare: asthenia<br />An apparent hypersensitivity syndrome has been reported rarely which has included some of the following<br />features: angioedema, lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis,<br />thrombocytopenia, eosinophilia, ESR increased, arthritis and arthralgia, urticaria, photosensitivity, fever,<br />flushing, dyspnoea and malaise.<br /><u><strong>Investigations:</strong></u><br />Rare:increases in serum transaminases (alanine aminotransferase, aspartate aminotransferase, &gamma;-glutamyl<br />transpeptidase) (see section 4.4 Hepatic effects), elevated alkaline phosphatase; increase in serum CK levels<br />(see section 4.4).<br />Increases in HbA1c and fasting serum glucose levels have been reported with statins, including Simva.</p><p>There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness,<br />amnesia, memory impairment, confusion) associated with statin use, including simvastatin. The reports are<br />generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day<br />to years) and symptom resolution (median of 3 weeks).<br />The following additional adverse events have been reported with some statins:<br />&bull; sleep disturbances, including nightmares<br />&bull; sexual dysfunction<br />&bull; Diabetes mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge;<br />5.6 mmol/L, BMI &gt; 30 kg/m2, raised triglycerides, history of hypertension).<br /><u><strong>Paediatric population</strong></u><br />In a 48-week study involving children and adolescents (boys Tanner Stage II and above and girls who were at<br />least one year post-menarche) 10-17 years of age with heterozygous familial hypercholesterolaemia (n = 175),<br />the safety and tolerability profile of the group treated with Simva was generally similar to that of the group<br />treated with placebo. The long-term effects on physical, intellectual, and sexual maturation are unknown. No<br />sufficient data are currently available after one year of treatment. (See sections 4.2, 4.4, and 5.1).&nbsp;</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To date, a few cases of overdosage have been reported; the maximum dose taken was 3.6 g. All patients<br />recovered without sequelae. There is no specific treatment in the event of overdose. In this case, symptomatic<br />and supportive measures should be adopted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: HMG-CoA reductase inhibitor<br />ATC-Code: C10A A01<br />Mechanism of action<br />After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed in the liver to the corresponding<br />active beta-hydroxyacid form which has a potent activity in inhibiting HMG-CoA reductase (3 hydroxy &ndash; 3<br />methylglutaryl CoA reductase). This enzyme catalyses the conversion of HMG-CoA to mevalonate, an early<br />and rate-limiting step in the biosynthesis of cholesterol.<br />Simva has been shown to reduce both normal and elevated LDL-C concentrations. LDL is formed from verylow-<br />density protein (VLDL) and is catabolised predominantly by the high affinity LDL receptor. The<br />mechanism of the LDL-lowering effect of Simva may involve both reduction of VLDL-cholesterol (VLDL-C)<br />concentration and induction of the LDL receptor, leading to reduced production and increased catabolism of<br />LDL-C. Apolipoprotein B also falls substantially during treatment with Simva. In addition, Simva moderately<br />increases HDL-C and reduces plasma TG. As a result of these changes the ratios of total- to HDL-C and LDLto<br />HDL-C are reduced.<br /><u><strong>Clinical efficacy and safety</strong></u><br /><u><strong>High Risk of Coronary Heart Disease (CHD) or Existing Coronary Heart Disease</strong></u><br />In the Heart Protection Study (HPS), the effects of therapy with Simva were assessed in 20,536 patients (age<br />40-80 years), with or without hyperlipidaemia, and with coronary heart disease, other occlusive arterial disease<br />or diabetes mellitus. In this study, 10,269 patients were treated with Simva 40 mg/day and 10,267 patients<br />were treated with placebo for a mean duration of 5 years. At baseline, 6,793 patients (33 %) had LDL-C levels<br />below 116 mg/dL; 5,063 patients (25 %) had levels between 116 mg/dL and 135 mg/dL; and 8,680 patients (42<br />%) had levels greater than 135 mg/dL.</p><p>Treatment with Simva 40 mg/day compared with placebo significantly reduced the risk of all cause mortality<br />(1328 [12.9 %] for simvastatin-treated patients versus 1507 [14.7 %] for patients given placebo; p = 0.0003),<br />due to an 18 % reduction in coronary death rate (587 [5.7 %] versus 707 [6.9 %]; p = 0.0005; absolute risk<br />reduction of 1.2 %). The reduction in non-vascular deaths did not reach statistical significance. Simva also<br />decreased the risk of major coronary events (a composite endpoint comprised of non-fatal MI or CHD death)<br />by 27 % (p &lt; 0.0001). Simva reduced the need for undergoing coronary revascularization procedures<br />(including coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) and peripheral<br />and other non-coronary revascularization procedures by 30 % (p &lt; 0.0001) and 16 % (p = 0.006), respectively.<br />Simva reduced the risk of stroke by 25 % (p &lt; 0.0001), attributable to a 30 % reduction in ischemic stroke (p &lt;0.0001). In addition, within the subgroup of patients with diabetes, Simva reduced the risk of developing<br />macrovascular complications, including peripheral revascularization procedures (surgery or angioplasty),<br />lower limb amputations, or leg ulcers by 21 % (p = 0.0293). The proportional reduction in event rate was<br />similar in each subgroup of patients studied, including those without coronary disease but who had<br />cerebrovascular or peripheral artery disease, men and women, those aged either under or over 70 years at entry<br />into the study, presence or absence of hypertension, and notably those with LDL cholesterol below 3.0 mmol/l<br />at inclusion.<br />In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with Simva on total mortality was<br />assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this<br />multicenter, randomised, double-blind, placebo-controlled study, patients with angina or a previous myocardial<br />infarction (MI) were treated with diet, standard care, and either Simva 20-40 mg/day (n = 2,221) or placebo (n<br />= 2,223) for a median duration of 5.4 years. Simva reduced the risk of death by 30 % (absolute risk reduction<br />of 3.3 %). The risk of CHD death was reduced by 42 % (absolute risk reduction of 3.5 %). Simva also<br />decreased the risk of having major coronary events (CHD death plus hospital-verified and silent nonfatal MI)<br />by 34 %. Furthermore, Simva significantly reduced the risk of fatal plus nonfatal cerebrovascular events<br />(stroke and transient ischemic attacks) by 28 %. There was no statistically significant difference between<br />groups in non-cardiovascular mortality.<br />The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)<br />evaluated the effect of treatment with Simva 80 mg versus 20 mg (median follow-up 6.7 yrs) on major vascular<br />events (MVEs; defined as fatal CHD, non-fatal MI, coronary revascularization procedure, non-fatal or fatal<br />stroke, or peripheral revascularization procedure) in 12,064 patients with a history of myocardial infarction.<br />There was no significant difference in the incidence of MVEs between the 2 groups; Simva 20 mg (n = 1553;<br />25.7 %) vs. Simva 80 mg (n = 1477; 24.5 %); RR 0.94, 95 % CI: 0.88 to 1.01. The absolute difference in LDLC<br />between the two groups over the course of the study was 0.35 &plusmn; 0.01 mmol/L. The safety profiles were<br />similar between the two treatment groups except that the incidence of myopathy was approximately 1.0 % for<br />patients on Simva 80 mg compared with 0.02 % for patients on 20 mg. Approximately half of these myopathy<br />cases occurred during the first year of treatment. The incidence of myopathy during each subsequent year of<br />treatment was approximately 0.1 %.<br /><u><strong>Primary Hypercholesterolaemia and Combined Hyperlipidaemia</strong></u><br />In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily in patients with<br />hypercholesterolemia, the mean reductions of LDL-C were 30, 38, 41 and 47 %, respectively. In studies of<br />patients with combined (mixed) hyperlipidaemia on simvastatin 40 mg and 80 mg, the median reductions in<br />triglycerides were 28 and 33 % (placebo: 2 %), respectively, and mean increases in HDL-C were 13 and 16 %<br />(placebo: 3 %), respectively.</p><p><u><strong>Paediatric population</strong></u><br />In a double-blind, placebo-controlled study, 175 patients (99 boys Tanner Stage II and above and 76 girls who<br />were at least one year post-menarche) 10-17 years of age (mean age 14.1 years) with heterozygous familial<br />hypercholesterolaemia (heFH) were randomized to simvastatin or placebo for 24 weeks (base study). Inclusion<br />in the study required a baseline LDL-C level between 160 and 400 mg/dL and at least one parent with an LDLC<br />level &gt; 189 mg/dL. The dosage of simvastatin (once daily in the evening) was 10 mg for the first 8 weeks,<br />20 mg for the second 8 weeks, and 40 mg thereafter. In a 24-week extension, 144 patients elected to continue<br />therapy and received simvastatin 40 mg or placebo.<br />Simva significantly decreased plasma levels of LDL-C, TG, and Apo B. Results from the extension at 48<br />weeks were comparable to those observed in the base study. After 24 weeks of treatment, the mean achieved<br />LDL-C value was 124.9 mg/dL (range: 64.0-289.0 mg/dL) in the Simva 40 mg group compared to 207.8<br />mg/dL (range: 128.0-334.0 mg/dL) in the placebo group.<br />After 24 weeks of simvastatin treatment (with dosages increasing from 10, 20 and up to 40 mg daily at 8- week<br />intervals), Simva decreased the mean LDL-C by 36.8 % (placebo: 1.1 % increase from baseline), Apo B by<br />32.4 % (placebo: 0.5 %), and median TG levels by 7.9 % (placebo: 3.2 %) and increased mean HDL-C levels<br />by 8.3 % (placebo: 3.6 %). The long-term benefits of Simva on cardiovascular events in children with heFH<br />are unknown.<br />The safety and efficacy of doses above 40 mg daily have not been studied in children with heterozygous<br />familial hypercholesterolaemia. The long-term efficacy of simvastatin therapy in childhood to reduce<br />morbidity and mortality in adulthood has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding beta-hydroxyacid, a<br />potent inhibitor of HMG-CoA reductase. Hydrolysis takes place mainly in the liver; the rate of hydrolysis in<br />human plasma is very slow.<br />The pharmacokinetic properties have been evaluated in adults. Pharmacokinetic data in children and<br />adolescents are not available.<br /><u><strong>Absorption</strong></u><br />In man simvastatin is well absorbed and undergoes extensive hepatic first-pass extraction. The extraction in the<br />liver is dependent on the hepatic blood flow. The liver is the primary site of action of the active form. The<br />availability of the beta-hydroxyacid to the systemic circulation following an oral dose of simvastatin was found<br />to be less than 5 % of the dose. Maximum plasma concentration of active inhibitors is reached approximately<br />1-2 hours after administration of simvastatin. Concomitant food intake does not affect the absorption.</p><p>The pharmacokinetics of single and multiple doses of simvastatin showed that no accumulation of medicinal<br />product occurred after multiple dosing.<br /><u><strong>Distribution</strong></u><br />The protein binding of simvastatin and its active metabolite is &gt; 95 %.<br /><u><strong>Elimination</strong></u><br />Simvastatin is a substrate of CYP3A4 (see sections 4.3 and 4.5). The major metabolites of simvastatin present<br />in human plasma are the beta-hydroxyacid and four additional active metabolites. Following an oral dose of<br />radioactive simvastatin to man, 13 % of the radioactivity was excreted in the urine and 60 % in the faeces<br />within 96 hours. The amount recovered in the faeces represents absorbed medicinal product equivalents<br />excreted in bile as well as unabsorbed medicinal product. Following an intravenous injection of the betahydroxyacid<br />metabolite, its half-life averaged 1.9 hours. An average of only 0.3 % of the IV dose was excreted<br />in urine as inhibitors.<br />Simvastatin acid is taken up actively into the hepatocytes by the transporter OATP1B1.<br /><em>Special Populations</em><br /><em>SLCO1B1 polymorphism</em><br />Carriers of the SLCO1B1 gene c.521T&gt;C allele have lower OATP1B1 activity. The mean exposure (AUC) of<br />the main active metabolite, simvastatin acid is 120% in heterozygote carriers (CT) of the C allele and 221% in<br />homozygote (CC) carriers relative to that of patients who have the most common genotype (TT). The C allele<br />has a frequency of 18% in the European population. In patients with SLCO1B1 polymorphism there is a risk of<br />increased exposure of simvastatin acid, which may lead to an increased risk of rhabdomyolysis (see section<br />4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on conventional animal studies regarding pharmacodynamics, repeated dose toxicity, genotoxicity and<br />carcinogenicity, there are no other risks for the patient than may be expected on account of the<br />pharmacological mechanism. At maximally tolerated doses in both the rat and the rabbit, simvastatin produced<br />no foetal malformations, and had no effects on fertility, reproductive function or neonatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1. Ludipress<br />2. Pregelatinised starch<br />3. Hydroxypropylcellulose<br />4. Crospovidone<br />5. Povidone<br />6. Croscarmellose sodium<br />7. Citric acid monohydrate<br />8. Microcrystalline Cellulose<br />9. Silicon Dioxide Colloidal<br />10. Magnesium Stearate<br /><strong>Coating material:</strong><br />11. Opadry white<br />12. Propylene glycol<br />13. Talc<br />14. Polysorbate 80<br />15. Butylated Hydroxyanisole<br />16. Simethicone<br />17. Purified Water<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, Keep out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Al-Foil &amp; PVC/ACLAR Film Clear&nbsp;</p><p>Outer carton&nbsp;</p><p>Patient information Leaflet&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06-11-2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>